AGX51，5MG，SML3635-5MG，Sigma

Biochem/physiol Actions

AGX51 is an antagonist that blocks transcriptional regulators ID1-4 from binding basic helix-loop-helix (bHLH) transcription factor E47, causing ubiquitin-mediated degradation of IDs (10-40 μM for 2-48h; HCT116). AGX51 reduces cell viability, G0/G1 growth arrest, and a reduction in cyclin D1 levels in cultures (5-40 μM for 4-24h; HUVEC and HCT116) and suppresses ocular neovascularization in mouse models of age-related macular degeneration (AMD) and retinopathy of prematurity (ROP) in vivo (500 μg/mouse via twice daily i.p. or 1-30 μg/eye via intravitreal injection immediately and 7 days after rupture of Bruch’s membrane).
Antagonist that blocks transcriptional regulators ID1-4 from binding basic helix-loop-helix (bHLH) transcription factor E47, causing ubiquitin-mediated ID degradation.